Lantheus Holdings, Inc. (BIT:1LNTH)

Market Cap	3.52B
Revenue (ttm)	1.30B
Net Income (ttm)	142.91M
Shares Out	n/a
EPS (ttm)	2.04
PE Ratio	24.62
Forward PE	11.58
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	9
Open	n/a
Previous Close	52.20
Day's Range	n/a
52-Week Range	42.02 - 95.18
Beta	n/a
RSI	65.38
Earnings Date	Nov 6, 2025

About Lantheus Holdings

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked o...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 1956
• Employees: 808
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1LNTH

Financial Performance

In 2024, Lantheus Holdings's revenue was $1.53 billion, an increase of 18.32% compared to the previous year's $1.30 billion. Earnings were $312.44 million, a decrease of -4.35%.

Financial numbers in USD